PT  - JOURNAL ARTICLE
AU  - Ide, Takafumi
AU  - Chiney, Manoj
AU  - Thanh Bach, Huynh Yen
AU  - Goti, Vineet
AU  - Murthy, Bindu
AU  - Hobar, Coburn
AU  - Zhao, Qihong
AU  - Aras, Urvi
TI  - LP-182 Pharmacokinetics, selectivity profile, and exposure-response relationship for efficacy and safety in a phase 2 study of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with systemic lupus erythematosus
AID  - 10.1136/lupus-2023-KCR.257
DP  - 2023 Jul 01
TA  - Lupus Science & Medicine
PG  - A155--A155
VI  - 10
IP  - Suppl 1
4099  - http://lupus.bmj.com/content/10/Suppl_1/A155.short
4100  - http://lupus.bmj.com/content/10/Suppl_1/A155.full
SO  - Lupus Sci Med2023 Jul 01; 10
AB  - Background Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in multiple countries for the treatment of adults with plaque psoriasis.¹ ² Deucravacitinib binds the unique TYK2 regulatory domain, conferring greater functional selectivity vs JAK inhibitors, which bind the catalytic domain. Deucravacitinib showed superior efficacy vs placebo in a phase 2 trial in SLE (NCT03252587).³ This analysis assessed the pharmacokinetics (PK), selectivity profile compared to JAK inhibitors, and exposure-response (E-R) relationship for efficacy and safety of deucravacitinib in SLE.Methods In the phase 2 trial, patients with active SLE were randomized 1:1:1:1 to placebo or deucravacitinib (3 mg BID, 6 mg BID, 12 mg QD). PK analysis included pooled concentration data from 266 SLE patients and 328 phase 1 participants. IC50 was determined by in vitro whole blood assays and plotted against PK profiles. E-R analyses included data from 356 patients. Logistic regression analyses assessed the relationship between deucravacitinib exposure and probability of achieving efficacy endpoints and safety events at weeks 32 and 48.Results Deucravacitinib PK in SLE patients was not meaningfully different from that in phase 1 participants. At 12 mg QD, deucravacitinib Cmax was 8-fold lower than JAK 1/3 IC50 and 47-fold lower than JAK 2/2 IC50 (figure 1). In the E-R analyses, the probability of achieving SRI(4) and BICLA at week 32 increased with increasing deucravacitinib CminSS, with 3 mg BID providing near-maximal response. The E-R relationship for infection and infestation was relatively flat, while skin and subcutaneous tissue disorders increased with increasing deucravacitinib CminSS. These E-R relationships were similar at week 48.Conclusions Deucravacitinib PK in SLE patients is not meaningfully different from that in phase 1 participants. At clinically relevant exposures, deucravacitinib demonstrates highly selective inhibition of TYK2 vs JAK 1/2/3. The deucravacitinib E-R relationships are well characterized for various efficacy endpoints and safety events.Abstract LP-182 Figure 1 Plasma concentration-time profile of deucravacitinib, baricitinib, tofacitinib, and upadacitinib along with their respective whole blood IC50 curvesReferencesArmstrong A, et al. J Am Acad Dermatol 2023;88(1):29–39.Strober B, et al. J Am Acad Dermatol 2023;88(1):40–51.Morand E, et al. Arthritis Rheumatol 2022 Nov 11 (Epub ahead of print).